Gel-Based Nanocarrier for Intravesical Chemotherapy Delivery: In Vitro and In Vivo Study.
Ting-Yu ChenMing-Jun TsaiI-Ling LinLi-Ching ChangPao-Chu WuPublished in: Pharmaceuticals (Basel, Switzerland) (2020)
Intravesical administration of chemotherapeutic agents can enhance drug accumulation in tumors and reduce systemic side effects. Nanocarriers were developed for intravesical administration and exploit the permeation enhancement effect. In vitro permeation evaluation, the drug transdermal amount and accumulation amounts in the tissue of gemcitabine-loaded nanocarriers through biological membrane significantly increased about 14.8~33.0-fold and 1.5~14.1-fold respectively, when compared to a control group of 1% gemcitabine saline solution. In in vivo intravesical administration, the drug accumulation amount in bladder tissue of nanocarrier of 75.2 ± 5.4 μg was revealed as being comparably higher than that of the control group of 44.8 ± 6.4 μg. In confocal laser scanning microscopy imagery, the penetration depth of fluorescent dyes-rhodamine was increased from 80 μm up to 120 μm when a nanocarrier was used. This result implies that the nanocarrier is a promising drug delivery agent for intravesical administration.
Keyphrases
- drug delivery
- muscle invasive bladder cancer
- urinary tract
- cancer therapy
- drug release
- optical coherence tomography
- locally advanced
- high resolution
- drug induced
- adverse drug
- squamous cell carcinoma
- high throughput
- fluorescent probe
- emergency department
- label free
- living cells
- hyaluronic acid
- radiation therapy
- aqueous solution